---
layout: default
title: Zanubrutinib
description: "Zanubrutinib çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 6 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 201
evidence_level: L5
indication_count: 6
---

# Zanubrutinib

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>6</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Zanubrutinibï¼šå¾ B ç´°èƒæ·‹å·´ç˜¤åˆ°éª¨é«“æ€§ç™½è¡€ç—…

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Zanubrutinib å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Zanubrutinib åŸæœ¬ç”¨æ–¼æ²»ç™‚è¢«å¥—ç´°èƒæ·‹å·´ç˜¤ã€è¯æ°å·¨çƒè›‹ç™½è¡€ç—‡ç­‰ B ç´°èƒæƒ¡æ€§è…«ç˜¤ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**éª¨é«“æ€§ç™½è¡€ç—… (myeloid leukemia)** æœ‰æ•ˆï¼Œ
æœ‰ **2 å€‹è‡¨åºŠè©¦é©—**å’Œ **9 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | è¢«å¥—ç´°èƒæ·‹å·´ç˜¤ (MCL)ã€è¯æ°å·¨çƒè›‹ç™½è¡€ç—‡ (WM)ã€CLL/SLLã€é‚Šç·£å€æ·‹å·´ç˜¤ã€æ¿¾æ³¡æ€§æ·‹å·´ç˜¤ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | myeloid leukemiaã€vertebral anomalies and variable endocrine and T-cell dysfunctionã€ganglioneuroblastoma (disease)ã€è…¹è†œå¾Œè…«ç˜¤ã€Ewing sarcomaã€ç¥ç¶“æ¯ç´°èƒç˜¤ |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.65% |
| è­‰æ“šç­‰ç´š | L2 (æœ‰è‡¨åºŠè©¦é©—æ”¯æŒ) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 1 å¼µ (æœ‰æ•ˆ) |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. myeloid leukemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.65%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Zanubrutinib æ˜¯é«˜é¸æ“‡æ€§çš„å¸ƒé­¯é “é…ªæ°¨é…¸æ¿€é…¶ (BTK) æŠ‘åˆ¶åŠ‘ã€‚
BTK åœ¨ B ç´°èƒå—é«” (BCR) è¨Šè™Ÿå‚³éä¸­æ‰®æ¼”é—œéµè§’è‰²ï¼ŒæŠ‘åˆ¶ BTK å¯é˜»æ–·æƒ¡æ€§ B ç´°èƒçš„å¢æ®–èˆ‡å­˜æ´»ã€‚

**ä½œç”¨æ©Ÿè½‰ï¼š**
- æŠ‘åˆ¶ BTK (Bruton tyrosine kinase)ï¼ŒIC50 ç´„ 20 nM
- ç›¸è¼ƒæ–¼ ibrutinibï¼Œå…·æœ‰æ›´é«˜çš„ BTK é¸æ“‡æ€§
- è¼ƒå°‘ off-target æ•ˆæ‡‰ï¼Œå¿ƒæˆ¿é¡«å‹•ç­‰å‰¯ä½œç”¨è¼ƒä½

é›–ç„¶ BTK ä¸»è¦è¡¨ç¾æ–¼ B ç´°èƒï¼Œä½†è¿‘å¹´ç ”ç©¶ç™¼ç¾ BTK åœ¨æŸäº›éª¨é«“æ€§æƒ¡æ€§è…«ç˜¤ä¸­ä¹Ÿæœ‰è¡¨ç¾ï¼Œ
é€™å¯èƒ½æ˜¯é æ¸¬ zanubrutinib å°éª¨é«“æ€§ç™½è¡€ç—…æœ‰æ•ˆçš„æ©Ÿè½‰åŸºç¤ã€‚

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT05665530](https://clinicaltrials.gov/study/NCT05665530) | Phase 1 | COMPLETED | 86 | PRT2527 (CDK9 æŠ‘åˆ¶åŠ‘) èˆ‡ zanubrutinib ä½µç”¨æ²»ç™‚å¾©ç™¼/é›£æ²»æ€§è¡€æ¶²æƒ¡æ€§è…«ç˜¤ |
| [NCT04477291](https://clinicaltrials.gov/study/NCT04477291) | Phase 1a/b | TERMINATED | 45 | CG-806 (luxeptinib) æ²»ç™‚å¾©ç™¼/é›£æ²»æ€§æ€¥æ€§éª¨é«“æ€§ç™½è¡€ç—…æˆ–é«˜é¢¨éšª MDS |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [39647999](https://pubmed.ncbi.nlm.nih.gov/39647999/) | 2025 | RCT Phase 3 | J Clin Oncol | SEQUOIA è©¦é©— 5 å¹´è¿½è¹¤ï¼šzanubrutinib vs BR åœ¨åˆæ²» CLL/SLL |
| [40334067](https://pubmed.ncbi.nlm.nih.gov/40334067/) | 2025 | Phase 2 | Blood Advances | Zanubrutinib åœ¨ ibrutinib/acalabrutinib ä¸è€å—æ‚£è€…ä¸­è€å—æ€§è‰¯å¥½ |
| [40829104](https://pubmed.ncbi.nlm.nih.gov/40829104/) | 2026 | è·¨è©¦é©—åˆ†æ | Blood Advances | Zanubrutinib åœ¨ del(17p)/TP53 çªè®Š CLL/SLL æ‚£è€…ä¸­çš„ç™‚æ•ˆåˆ†æ |
| [34959482](https://pubmed.ncbi.nlm.nih.gov/34959482/) | 2021 | å›é¡§ | Pharmaceutics | TKI æ™‚ä»£çš„æ…¢æ€§ç™½è¡€ç—…ï¼šBTK æŠ‘åˆ¶åŠ‘åœ¨ CLL ä¸­çš„è§’è‰² |
| [36402930](https://pubmed.ncbi.nlm.nih.gov/36402930/) | 2023 | å›é¡§ | Leukemia | BTK æŠ‘åˆ¶åŠ‘åœ¨è¯æ°å·¨çƒè›‹ç™½è¡€ç—‡ä¸­çš„æ‡‰ç”¨ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. vertebral anomalies and variable endocrine and T-cell dysfunction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.38%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.38%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. ganglioneuroblastoma (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.36%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.36%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. retroperitoneal neoplasm</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.30%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.30%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. Ewing sarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.27%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.27%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. neuroblastoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.21%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.21%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ ¸å‡†æ—¥æœŸ |
|---------|------|------|-------------|---------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028160è™Ÿ | ç™¾æ‚…æ¾¤è† å›Š 80 æ¯«å…‹ | è† å›ŠåŠ‘ | è‡ºç£ç™¾æ¿Ÿç¥å·æœ‰é™å…¬å¸ | 2021/09/15 |

**æ ¸å‡†é©æ‡‰ç—‡ï¼š**
1. å…ˆå‰æ›¾æ¥å—è‡³å°‘ä¸€ç¨®æ²»ç™‚çš„è¢«å¥—ç´°èƒæ·‹å·´ç˜¤ (MCL) æˆäººç—…äºº
2. è¯æ°å·¨çƒè›‹ç™½è¡€ç—‡ (WM) æˆäººç—…äºº
3. å…ˆå‰æ›¾æ¥å—è‡³å°‘ä¸€ç¨®æŠ— CD20 ç™‚æ³•çš„å¾©ç™¼æˆ–é ‘å›ºå‹é‚Šç·£å€æ·‹å·´ç˜¤ (MZL) æˆäººç—…äºº
4. æ…¢æ€§æ·‹å·´çƒæ€§ç™½è¡€ç—… (CLL)/å°æ·‹å·´çƒæ€§æ·‹å·´ç˜¤ (SLL) æˆäººç—…äºº
5. ä½µç”¨ obinutuzumab é©ç”¨æ–¼å…ˆå‰æ›¾æ¥å—è‡³å°‘ 2 ç¨®æ²»ç™‚çš„æ¿¾æ³¡æ€§æ·‹å·´ç˜¤ (FL) æˆäººç—…äºº

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | æ¨™é¶æ²»ç™‚è—¥ç‰© (éå‚³çµ±ç´°èƒæ¯’æ€§) |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | ä¸­åº¦ (å—œä¸­æ€§ç™½è¡€çƒæ¸›å°‘ã€è¡€å°æ¿æ¸›å°‘) |
| å‡ºè¡€é¢¨éšª | éœ€æ³¨æ„ï¼Œå°¤å…¶èˆ‡æŠ—å‡è¡€åŠ‘ä½µç”¨æ™‚ |
| ç›£æ¸¬é …ç›® | CBC (å«åˆ†é¡)ã€è‚åŠŸèƒ½ã€å‡ºè¡€å¾µå…† |
| è™•ç½®é˜²è­· | å£æœè—¥ç‰©ï¼Œä¾ä¸€èˆ¬è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œ |

## å®‰å…¨æ€§è€ƒé‡

**ä¸»è¦è—¥ç‰©äº¤äº’ä½œç”¨ (Major)ï¼š**

| è—¥ç‰©é¡åˆ¥ | ä»£è¡¨è—¥ç‰© | äº¤äº’ä½œç”¨æ©Ÿè½‰ |
|---------|---------|-------------|
| æŠ—å‡è¡€åŠ‘/æŠ—è¡€å°æ¿ | Warfarin, Apixaban, Clopidogrel, Aspirin | å¢åŠ å‡ºè¡€é¢¨éšª |
| CYP3A å¼·æ•ˆæŠ‘åˆ¶åŠ‘ | Ketoconazole, Clarithromycin, Cobicistat | å¢åŠ  zanubrutinib è¡€ä¸­æ¿ƒåº¦ |
| CYP3A å¼·æ•ˆèª˜å°åŠ‘ | Enzalutamide, Apalutamide, Mitotane | é™ä½ zanubrutinib è¡€ä¸­æ¿ƒåº¦ |
| å…¶ä»– BTK æŠ‘åˆ¶åŠ‘ | Ibrutinib, Acalabrutinib | è—¥ç†ä½œç”¨é‡ç–Š |
| å…ç–«æŠ‘åˆ¶åŠ‘ | Adalimumab, Etanercept, Infliximab | å¢åŠ æ„ŸæŸ“é¢¨éšª |

**æ³¨æ„äº‹é …ï¼š**
- æ¥å—æ‰‹è¡“å‰éœ€æš«åœä½¿ç”¨ (è¡“å‰è‡³å°‘ 3-7 å¤©)
- B å‹è‚ç‚å†æ´»åŒ–é¢¨éšªï¼Œéœ€ç›£æ¸¬ HBsAg/anti-HBc
- å¿ƒæˆ¿é¡«å‹•é¢¨éšªè¼ƒ ibrutinib ä½ï¼Œä½†ä»éœ€ç›£æ¸¬

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**è‘¡è„æŸšæ± (grapefruit juice)** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šGrapefruit and/or grapefruit juice may increase the plasma concentrations of zanubrutinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain...
- å»ºè­°ï¼šZanubrutinib may be administered with or without food.  Patients should avoid consumption of grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with zanubrutinib.



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Arrhythmias, Cardiac** ğŸŸ¡ Moderate
- Atrial fibrillation and atrial flutter have occurred in patients treated with zanubrutinib monotherapy.  Care should be exercised when using this agent in patients with cardiac risk factors, hypertension, and acute infections as they may be at increa...

**Hemorrhage** ğŸŸ¡ Moderate
- Fatal and serious hemorrhagic events have occurred in patients with hematological malignancies treated with zanubrutinib.  These complications have occurred in patients with and without concomitant antiplatelet or anticoagulation therapy.  Special ca...

**Pancytopenia** ğŸŸ¡ Moderate
- Cytopenias, including neutropenia, thrombocytopenia, and anemia were reported in patients treated with zanubrutinib.  Care should be taken when using this agent in patients with hematological abnormalities.  It is recommended to monitor complete bloo...

**Hepatic Insufficiency** ğŸŸ¡ Moderate
- The safety of zanubrutinib has not been evaluated in patients with severe hepatic impairment.  Dosage modification of zanubrutinib is recommended in patients with severe hepatic impairment.  The recommended dose for patients with severe hepatic impai...

**Infections** ğŸŸ¡ Moderate
- Fatal and serious infections including bacterial, viral, or fungal and opportunistic infections have occurred in patients with hematological malignancies treated with zanubrutinib.  Consider prophylaxis for herpes simplex virus, pneumocystis jiroveci...

*å¦æœ‰ 1 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
é›–ç„¶ zanubrutinib çš„ä¸»è¦ä½œç”¨åœ¨ B ç´°èƒï¼Œä½†å…¶åœ¨è¡€æ¶²æƒ¡æ€§è…«ç˜¤ä¸­çš„å»£æ³›ç™‚æ•ˆå·²ç²è­‰å¯¦ã€‚
é‡å°éª¨é«“æ€§ç™½è¡€ç—…çš„é æ¸¬æœ‰åˆæ­¥è‡¨åºŠè©¦é©—æ”¯æŒï¼Œä½†é€™äº›è©¦é©—ä¸»è¦æ¢è¨è¯åˆç”¨è—¥è€Œéå–®ç¨ä½¿ç”¨ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- ç¢ºèª BTK åœ¨éª¨é«“æ€§ç™½è¡€ç—…ä¸­çš„è¡¨ç¾èˆ‡åŠŸèƒ½
- è¨­è¨ˆå°ˆé–€é‡å°éª¨é«“æ€§ç™½è¡€ç—…çš„ Phase 1/2 è‡¨åºŠè©¦é©—
- è©•ä¼°èˆ‡ç¾æœ‰éª¨é«“æ€§ç™½è¡€ç—…æ²»ç™‚è—¥ç‰©çš„è¯åˆæ•ˆæœ
- å»ºç«‹ç”Ÿç‰©æ¨™è¨˜é æ¸¬å¯èƒ½å—ç›Šçš„æ‚£è€…äºç¾¤


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Tizanidine]({{ "/drugs/tizanidine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Denosumab]({{ "/drugs/denosumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cerliponase Alfa]({{ "/drugs/cerliponase_alfa/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Insulin Lispro]({{ "/drugs/insulin_lispro/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ferrous Gluconate]({{ "/drugs/ferrous_gluconate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Zanubrutinibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/zanubrutinib/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_zanubrutinib,
  title = {Zanubrutinibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/zanubrutinib/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
